At the end of their cycle, hematocrit amounts had amplified by 3%-stage as opposed with baseline. The rise was not connected to for a longer time use or better AAS dose. A reason for this might be that, further than a specific level of androgenic action, no even more boost of hematocrit occurs: a ‘ceiling outcome’. Notably, While only five% of